ETON
NASDAQ · Pharmaceuticals
Eton Pharmaceuticals Inc
$23.76
+0.79 (+3.44%)
Financial Highlights (FY 2026)
Revenue
38.18M
Net Income
-3,740,365
Gross Margin
60.0%
Profit Margin
-9.8%
Rev Growth
+21.4%
D/E Ratio
1.22
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 60.0% | 60.0% | 34.9% | 34.9% |
| Operating Margin | -6.7% | -6.0% | 14.4% | 15.1% |
| Profit Margin | -9.8% | -9.3% | 13.3% | 11.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 38.18M | 31.46M | 122.17M | 107.30M |
| Gross Profit | 22.91M | 18.88M | 42.65M | 37.45M |
| Operating Income | -2,542,559 | -1,885,705 | 17.64M | 16.16M |
| Net Income | -3,740,365 | -2,774,065 | 16.25M | 12.60M |
| Gross Margin | 60.0% | 60.0% | 34.9% | 34.9% |
| Operating Margin | -6.7% | -6.0% | 14.4% | 15.1% |
| Profit Margin | -9.8% | -9.3% | 13.3% | 11.8% |
| Rev Growth | +21.4% | +21.4% | -8.5% | +2.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 153.07M | 153.07M | 24.71M | 28.65M |
| Total Equity | 125.43M | 125.43M | 125.41M | 143.27M |
| D/E Ratio | 1.22 | 1.22 | 0.20 | 0.20 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -1,419,108 | -1,110,962 | 25.36M | 21.76M |
| Free Cash Flow | — | — | 11.15M | 16.18M |